COMMUNIQUÉS West-GlobeNewswire

Dyadic and Fermbox Bio Launch First Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free)
04/03/2026
JUPITER, Fla. and BENGALURU, India, March 04, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company producing precision- [...]
Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates
04/03/2026
On track to submit Conditional Marketing Authorization for iopofosine I 131 to European Medicines Agency in Q3 2026 for potential 2027 EU commercialization as a treatment for Waldenström Macroglobulinemia Initiated [...]
Fennec Pharmaceuticals Announces Clinical Research Collaboration with Tampa General Hospital Cancer Institute
04/03/2026
Study is Real-World Evaluation of the Clinical Utility of Sodium Thiosulfate Injection (PEDMARK®) in Reducing the Risk of Ototoxicity in Adolescent and Young Adult (AYA) and Adult Patients with Non-Metastatic Solid [...]
Rezolute to Participate in the Citizens Life Sciences Conference
04/03/2026
REDWOOD CITY, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of [...]
Can-Fite’s Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study
04/03/2026
Ramat Gan, Israel, March 04, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs for the [...]
Boundless Bio to Participate in the Leerink Global Healthcare Conference
04/03/2026
SAN DIEGO, March 04, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with [...]
From Pain to Prevention: How Dubai’s Urologist is Saving Kidneys and Lifestyles
04/03/2026
Dr. Kamalesh, Urologist in Dubai, Shares Essential Tips for Preventing Kidney Stones in the UAE Climate DUBAI, United Arab Emirates, March 04, 2026 (GLOBE NEWSWIRE) -- As temperatures remain a focal point for residents [...]
RadNet, Inc. Reminds Investors of the Dedicated Conference Call and Presentation About the Recently Completed Acquisition of Gleamer SAS
04/03/2026
LOS ANGELES, March 04, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT) , a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient [...]
New data reveals 9 in 10 people prefer EURneffy, a needle-free nasal adrenaline spray, over auto-injectors
04/03/2026
ALK presents new findings that directly compare user preference between needle-free nasal and injectable adrenaline treatments for anaphylaxis, demonstrating that 88% of participants prefer EUR neffy ® —the first and [...]
Theolytics Awarded €8 million in Horizon Europe 2025 Grant Funding to Advance Phase 2 Study of THEO-260 in Ovarian Cancer
04/03/2026
Pending final negotiation, grant will fund up to 20 patients in the OCTOPOD-IV Phase 2a expansion study of THEO-260 in platinum-resistant ovarian cancer Competitive funding award highlights Theolytics’ innovative [...]
Philips unveils Rembra CT at ECR 2026, setting a new benchmark for speed and patient access designed to support diagnostic confidence for acute and high-demand imaging environments
04/03/2026
March 4, 2026 CE Marked and 510(k) pending, Rembra’s advanced image reconstruction technology delivers up to 106 images per second [1] and a high throughput of up to 270 patients per day [2] to support faster diagnosis [...]
BioVersys Announces Publication of BV100 Phase 1 Clinical Data in Journal of Antimicrobial Agents and Chemotherapy
04/03/2026
BASEL, Switzerland, March 04, 2026 (GLOBE NEWSWIRE) -- BV100 Phase 1, single- and multiple-ascending dose clinical trial data include pharmacokinetics, safety and tolerability data. BV100 demonstrated a dose- [...]
Nxera Pharma Submits Marketing Authorization Application for Daridorexant in South Korea
04/03/2026
Daridorexant is a dual orexin receptor antagonist being developed in South Korea by Nxera for the treatment of adult patients with insomnia and is approved and marketed in Japan as QUVIVIQ® Phase 3 trial of daridorexant [...]
HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid Tumors
04/03/2026
— Second clinical candidate from HUTCHMED’s next-generation ATTC platform — — Leveraging synergy through simultaneous inhibition of PAM pathway and EGFR signaling — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March [...]
Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results
04/03/2026
REYKJAVIK, Iceland, March 04, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients [...]
Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results
04/03/2026
REYKJAVIK, ICELAND (March 4, 2026) — Alvotech (NASDAQ: ALVO) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today [...]
Réaction aux attaques visant Carbios et ses dirigeants
04/03/2026
Clermont-Ferrand (France), 4 mars 2026 (08h45 CET). Carbios (Euronext Growth Paris : ALCRB) dénonce la campagne de déstabilisation dont elle fait l’objet depuis plusieurs mois et conteste formellement l’ensemble des [...]
Independent study presented at ECR highlights REGENERA™ bioresorbable scaffold potential for breast restoration after lumpectomy
04/03/2026
Independent investigators from the University of Pisa presented new data at the 2026 European Congress of Radiology (ECR) Ultrasound follow-up documented predictable scaffold bioresorption and progressive soft-tissue [...]
Response to attacks against Carbios and its executives
04/03/2026
Clermont-Ferrand (France), March 4, 2026 (8:45 a.m. CET). Carbios (Euronext Growth Paris : ALCRB) denounces the destabilization operation to which it has been subjected for several months and formally contests all [...]

Pages